NeuVasQ: An innovative approach to fight against neurovascular and neurodegenerative diseases
From disruptive research of scientific founder Benoit Vanhollebeke (WELBIO - ULB) to the development of blood-brain barrier pharmaceuticals aiming at repairing neurovascular function and neurodegenerative diseases.
D. welbionis : potential implications for metabolic diseases
A new bacterium, made in Belgium
Patrice Cani (WELBIO - UCLouvain) describes the properties displayed by D. welbionis, a new bacterium present in 70% of the population, that open the doors for potential treatment for type 2 diabetes, obesity and inflammatory diseases.
Wobble transfer RNA modifications optimize dynamic proteome expression
Pierre Close (WELBIO – ULiège) and Francesca Rapino describe how the regulation of transfer RNAs and modification of their anticodon impact the dynamics of protein synthesis and regulate protein folding and stability.
Maladies auto-immunes, des signatures moléculaire similaires au niveau des tissus cibles ?
L'utilisation d'inhibiteurs de TYK2 - déjà utilisés pour d'autres maladies auto-immunes - protège les cellules β contre les dommages induits par le système immunitaire
Decio Eizirik (WELBIO - ULB) et son équipe décrivent des signatures moléculaires similaires entre différentes maladies auto-immunes, identifiant des voies clés qui pourraient être ciblées pour la thérapie.
Cancer: Tumor driver promoting EMT, metastasis and resistance to therapy
New therapy for FAT1 mutated cancers
Cédric Blanpain (WELBIO – ULB) and his team identify the functions of FAT1, one of the most frequently mutated cancer gene drivers, uncovering that FAT1 mutations promote invasive features, metastasis and resistance to commonly used anti-cancer drugs
Important collaboration agreement with Kaneka Eurogentec
From fundamental research on bacterial stress to the production of biomedicines.
The use of biomedicines is disrupting current medicine
Kaneka and its Walloon subsidiary, Kaneka Eurogentec S.A., enter into a partnership with Jean-François Collet's laboratory (WELBIO - UCLouvain) by funding a new joint research group at the Duve Institute.
A ‘jammer’ blocks communication between the gut and the brain
This jammer prevents proper regulation of sugar, causing insulin resistance in people with diabetes. Patrice Cani (WELBIO - UCLouvain) and Claude Knauf (INSERM) also discover that a lipid produced by our body helps preventing this dysfunction.
Combining two complementary immunotherapies increases the efficacy of treatments against cancer
Sophie Lucas (WELBIO – UCLouvain) and her team neutralize a molecule that blocks immune responses against cancer. This novel form of immunotherapy induces tumor regressions by strongly increasing the efficacy of another well-known immunotherapy.